Sun Pharma plunges 10% as insider trading case may reopen
Sun Pharma shares plunged as much as 10.4% on Monday following reports that SEBI may reopen an insider trading case against the drugmaker. This comes after a whistleblower reportedly alleged financial irregularities by the company, MD Dilip Shanghvi and others. In August 2017, Sun Pharma, Shanghvi and nine others settled an insider trading probe after paying â¹18 lakh settlement charges. 